A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America

Xochilcal-Morales, M.; Castro, Elena Martín-de; Guajardo-Rosas, Jorge; Obregón, T. N.; Acevedo, Juan Carlos; Chucan, J. M. G.; Plancarte-Sánchez, Ricardo; Davila, G.; Wajsbrot, Dalia; Guerrero, M. Eugenia; Vinueza, Raúl

doi:10.1111/j.1742-1241.2010.02389.x

Cited by 12 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, similar findings were reported in prospective real-world studies involving patients with NeP. The median durations of pregabalin use were 84.0 days in a Latin American multicenter, open-label study [20], and 62 days in a Greek noninterventional, multicenter study [21]. In the present study, the persistence rates were 29.3% and 12.1% at 90 days and one year, respectively, indicating only a minority of patients continued to use pregabalin.…”

Section: Discussionsupporting

confidence: 88%

“…On the other hand, the mean daily dose was 301 mg in a German open-label multicenter study for patients with DPNP and PHN [29]. Besides, the average doses in the first, second, and third month and after three months of treatment for NeP were 148.4, 145.3, 169.3, and 240.7 mg/day, respective, in a Danish study of peripheral NeP [30], and 42.6% and 38.9% of patients achieved a daily dose of 300 mg and 600 mg, respectively, in the Latin American NeP study [20]. The exact cause why the average dose used in the current study was lower than in some earlier reports was unknown.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

et al. 2020

View full text Add to dashboard Cite

Background: Pregabalin is approved for the treatment of neuropathic pain, fibromyalgia, and seizure disorders, although the pivotal trials were mostly carried out in Europe or North America. The prescribing patterns among different indications in Asia have rarely been explored. Methods: This was a population-based retrospective cohort study based on the National Health Insurance Research Database in Taiwan. Prescriptions of pregabalin were identified, and data regarding demographics, indications, coexisting diagnoses, and concomitant medications were extracted. Pregabalin users were followed for at least one year, and factors associated with persistence at one year were determined by using multivariate logistic regression analysis. Results: Between June 2012 and December 2016, 114,437 pregabalin users (mean age 60.7 ± 15.4 years, 57.8% female) were identified. The indications included post-herpetic neuralgia (PHN) (30.5%), musculoskeletal diseases other than fibromyalgia (21.2%), fibromyalgia (18.4%), diabetic peripheral neuropathic pain (DPNP) (11.7%) and epilepsy (2.9%). Overall, 62.5% and 6.4% of patients achieved a maximum dose of ≥150 and ≥ 300 mg/day, respectively. The median duration of persistent pregabalin use was 28 days (interquartile range 14-118 days). The one-year persistence rate was 12.1%, and the indications associated with the highest and lowest persistence rates were epilepsy (42.4%) and PHN (6.1%), respectively. Male gender (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.09-1.18), older age (OR 1.01 per year, 95% CI 1.01-1.01), indications other than PHN, especially epilepsy (OR 8.04, 95% CI 7.33-8.81, PHN as reference), and a higher initial dose (OR 1.12 per 75 mg, 95% CI = 1.10-1.15) were associated with persistence at one year, whereas the initial concomitant use of antiviral agents decreased the likelihood (OR 0.41, 95% CI 0.35-0.47). Conclusions: Pregabalin prescriptions for pain disorders were limited to short-term use, which is consistent around the world. However, the average prescribed dose in Taiwan was lower than those in Western countries, and was frequently below the recommended ranges. Potential causes included the duration of natural history of PHN, and off-label prescriptions for pain in acute herpes zoster, rather than PHN, as well as intolerance to the side effects.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Davari, et al due to SCI [18,19]. Both drugs have been shown to be effective in the treatment of neuropathic pain due to postherpetic neuralgia [20][21][22][23][24][25][26] and diabetic peripheral neuropathy [24][25][26][27][28][29]. PGB is the new generation of gabapentinoids that acts similar to GBP [30].…”

Section: Introductionmentioning

confidence: 99%

Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis

Davari

Amani

et al. 2020

Korean J Pain

View full text Add to dashboard Cite

“…On the other hand, the mean daily dose was 301 mg in a German open-label multicenter study for patients with DPNP and PHN (29). Besides, the average doses in the first, second, and third month and after three months of treatment for NeP were 148.4, 145.3, 169.3, and 240.7 mg/day, respective, in a Danish study of peripheral NeP (30), and 42.6% and 38.9% of patients achieved a daily dose of 300 mg and 600 mg, respectively, in the Latin American NeP study (20). The exact cause why the average dose used in the current study was lower than in some earlier reports was unknown.…”

Section: Discussionmentioning

confidence: 96%

Persistence of Pregabalin Treatment in Taiwan: a Nation-Wide Population-Based Study

Wang

Chen

Tsai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Pregabalin is approved for the treatment of neuropathic pain, fibromyalgia, and seizure disorders, although the pivotal trials were mostly carried out in Europe or North America. The prescribing patterns among different indications in Asia have rarely been explored.Methods This was a population-based retrospective cohort study based on the National Health Insurance Research Database in Taiwan. Prescriptions of pregabalin were identified, and data regarding demographics, indications, co-existing diagnoses, and concomitant medications were extracted. Pregabalin users were followed for at least one year, and factors associated with persistence at one year were determined by using multivariate logistic regression analysis.Results Between June 2012 and December 2016, 114,437 pregabalin users (mean age 60.7±15.4 years, 57.8% female) were identified. The indications included post-herpetic neuralgia (PHN) (30.5%), musculoskeletal diseases other than fibromyalgia (21.2%), fibromyalgia (18.4%), diabetic peripheral neuropathic pain (DPNP) (11.7%) and epilepsy (2.9%). Overall, 62.5% and 6.4% of patients achieved a maximum dose of ≥150 and ≥300 mg/day, respectively. The median duration of persistent pregabalin use was 28 days (interquartile range 14-118 days). The one-year persistence rate was 12.1%, and the indications associated with the highest and lowest persistence rates were epilepsy (42.4%) and PHN (6.1%), respectively. Male gender (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.09-1.18), older age (OR 1.01 per year, 95% CI 1.01-1.01), indications other than PHN, especially epilepsy (OR 8.04, 95% CI 7.33-8.81, PHN as reference), and a higher initial dose (OR 1.12 per 75 mg, 95% CI=1.10-1.15) were associated with persistence at one year, whereas the initial concomitant use of antiviral agents decreased the likelihood (OR 0.41, 95% CI 0.35-0.47).Conclusions Pregabalin prescriptions for pain disorders were limited to short-term use, which is consistent around the world. However, the average prescribed dose in Taiwan was lower than those in Western countries, and was typically frequently below the recommended ranges. Potential causes included the duration of natural history of PHN, and off-label prescriptions for pain in acute herpes zoster, rather than PHN, as well as intolerance to the side effects.

show abstract

A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America

Abstract: Flexible-dose pregabalin (150-600 mg/day) significantly reduced pain and anxiety and improved sleep and was generally well tolerated in Latin American patients with neuropathic pain.

Cited by 12 publications

References 24 publications

Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis

Persistence of Pregabalin Treatment in Taiwan: a Nation-Wide Population-Based Study

Contact Info

Product

Resources

About